Casdin Capital
Crossover fundNew York · Seed–Series C · 39 people tracked
Also known as CASDIN CAPITAL, LLC
Investment thesis
Casdin Capital invests across the life sciences sector, spanning healthcare, biotechnology, synthetic biology, and technology. The firm believes great medicines make great investments and targets companies leveraging the growing ability to read and manipulate molecular information. Its approach centers on partnering with companies and building positions to create value over time, emphasizing patience, persistence, and strong relationships. The firm's guiding formula is to aim at large markets, back great ideas and teams, stay focused, and avoid hubris. With decades of experience, Casdin positions itself as one of the few expert investors in the field.
Source: firm website, verified Aug 3, 2026.
Team · 39 people
from the firm's website
What they invest in
from 19 of 23 portfolio companiesBiotech ×16AI & Machine Learning ×8Deep Tech ×5Healthtech ×4Medical Devices ×4Advanced Manufacturing ×2Data & Infrastructure ×2Digital Health ×2
HQs:United States×19United Kingdom×1
Investments · 23 tracked
founders shown can be your intro pathAbsci uses AI and wet lab research in iterative cycles to design novel antibody therapeutics and biologics for drug discovery.
AI & Machine LearningBiotechDeep TechPortland, US
Zach Jonasson(Director)Bryan Lawlis(Director)Phil Barish(Executive Officer)Daniel Gold(Director)Sean McClain(Executive Officer)
Board seatEli Casdin· per SEC Form D · $125M raise · filed Mar 2021
Philadelphia, US
Board seatEli Casdin· per SEC Form D · $160M raise · filed Mar 2021
BiotechNew York, US
Asaf Zviran(Executive Officer, Director)Ezra Sofer(Executive Officer, Director)
BoardAlex Parker(Director)Shaun Rodriguez(Director)
Board seatEli Casdin· per SEC Form D · $100M raise · filed Apr 2021
BiotechCambridge, US
Abbie Celniker(Director)Alexandra Glucksmann(Executive Officer, Director)Dominik Naczynski(Director)Eli Casdin(Director)Chris Bowden(Director)Neil Exter(Director)
Board seatEli Casdin· per SEC Form D · $82.6M raise · filed Oct 2021
Genomatica uses biotechnology to replace fossil fuel-derived molecules with plant-based alternatives for use in consumer products, chemicals, and materials.
BiotechCleantechClimate TechSan Diego, US
Rasmus von Gottberg(Executive Officer)Thomas McDonald(Executive Officer)Christophe Schilling(Executive Officer, Director)Craig Binetti(Director)David Muldoon(Executive Officer)Anders Bendsen Spohr(Director)
Board seatEli Casdin· per SEC Form D · $119.1M raise · filed Aug 2021
HealthtechNew York, US
Jeffrey Lightcap(Director)Eli Casdin(Director)David Klimstra(Executive Officer)Peter Hamilton(Executive Officer)Antoine Munfa(Director)William Andrew Moye(Executive Officer, Director)
Board seatEli Casdin· per SEC Form D · $39M raise · filed Mar 2023
Boulder, US
Board seatEli Casdin· per SEC Form D · $250M raise · filed Jan 2021
BiotechSan Francisco, US
Amy Duross(Executive Officer)Nigel Darby(Director)Jason Bowman(Executive Officer)Rowan Chapman(Director)
Board seatEli Casdin· per SEC Form D · $75M raise · filed Nov 2020
23andMe operates a research platform that collects genetic data from millions of users to advance genomic research and health discovery.
BiotechDigital HealthDirect to ConsumerHealthtechLongevityMountain View, US
Anne Wojcicki(Co-founder & CEO)Linda Avey(Co-founder)Paul Cheung(Co-founder)Andrew Page(Executive Officer, Director)Esther Dyson(Director)Kathy Hibbs(Executive Officer)
Asimov develops a computer-aided design platform for genetic engineering, enabling designers to program living cells by applying abstraction, standardization, and modeling to biology.
AI & Machine LearningBiotechDeveloper ToolsBoston, US
Chris Voigt(Co-founder)Doug Densmore(Co-founder)Alec Nielsen(Co-founder & CEO)Raja Srinivas(Co-founder)
Asimov builds a computer-aided design platform for genetic engineering and synthetic biology, enabling genetic designers to program living cells through automated circuit design and computational modeling.
AI & Machine LearningBiotechDeep TechBoston, US
Chris Voigt(Co-founder)Doug Densmore(Co-founder)Alec Nielsen(Co-founder & CEO)Raja Srinivas(Co-founder)
Boston, US
Caitlin Donovan(Director)Pavel Raifeld(Director)Jacob A. Donoghue, M.D., Ph.D.(Executive Officer, Director)Jarrett Revels(Executive Officer)Naveen Rao(Director)Jacob A. Donoghue(Executive Officer, Director, Promoter)
City Therapeutics develops RNAi-based medicines targeting rare, specialty, and prevalent diseases using engineered trigger molecules and precision delivery ligands.
BiotechMedical DevicesCambridge, US
Mark Keating, MD(Co-founder)Kotaro Nakanishi, PhD(Co-founder)Yukihide Tomari, PhD(Co-founder)Phillip Zamore, PhD(Co-founder)
Dyno Therapeutics develops artificial intelligence-powered genetic technologies for gene therapy, specifically engineering adeno-associated virus (AAV) capsids to improve gene delivery for treating genetic diseases.
AI & Machine LearningBiotechWatertown, US
Eric Kelsic(CEO & Cofounder)Sam Sinai(Vice President, Head of ML & Cofounder)Adrian Veres(Chief Scientific Officer & Cofounder)George Church(Scientific Cofounder)Tomas Bjorklund(Scientific Co-founder)Alan Crane(Executive Chairman & Cofounder, Polaris Entrepreneur Partner)
Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.
BiotechDeep TechMedical Devices
David Liu, PhD(Founder)Alan Saghatelian, PhD(Co-Founder)David LiuAlan Saghetelian
Fabric Genomics provides an AI-based platform for next-generation sequencing (NGS) analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing.
AI & Machine LearningBiotechDigital HealthHealthtechMedical Devices
Martin Reese(Co-Founder, President, and CEO)Erwin Frise(Vice President of Technology and Data Science)
insitro is a drug discovery and development company that uses machine learning and cellular data to identify therapeutic insights and accelerate the creation of new medicines.
AI & Machine LearningBiotechSouth San Francisco, US
Daphne Koller(CEO & Founder)Robert Nelsen(Director)Vijay Pande(Director)Duane Valz(General Counsel)Mary Rozenman(Chief Financial Officer)
Komodo integrates healthcare data across providers, health systems, care settings, and payers to deliver insights on disease incidence, treatment patterns, and health outcomes.
AI & Machine LearningData & InfrastructureHealthtechSan Francisco, US
Dr. Arif Nathoo(Co-Founder/Co-CEO)Web Sun(Co-Founder/Co-CEO)
New York, US
Koda Mike Wang(Executive Officer, Director)Timothy Luke Sherwin(Director)
Multiply Labs builds robotic systems that automate biologics manufacturing for pharmaceutical companies.
Advanced ManufacturingBiotechDeep TechRoboticsSan Francisco, US
Fred Parietti(Founder/CEO)inAlice Melocchi(Founder)inMichael Doherty(Director)
BoardShaun Rodriguez(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Frequently asked questions
- What stage does Casdin Capital invest at?
- Casdin Capital invests at the Seed, Series A, Series B, Series C stages.
- What sectors does Casdin Capital focus on?
- Casdin Capital focuses on AI & Machine Learning, Biotech, Deep Tech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is Casdin Capital located?
- Casdin Capital is headquartered in New York, US.
- Does Casdin Capital lead rounds?
- Casdin Capital typically participates in rounds rather than leading them.
Media · Podcasts & interviews
featuring the teamEli Casdin – Casdin Capital (Manager Meetings, EP.02)
Capital Allocators with Ted Seides · Eli Casdin
The full interview with Casdin Capital's Eli Casdin
Eli Casdin · cnbc.com
Co-investors · 10
GV (formerly Google Ventures) is a venture investment firm that backs founders across many industries, aiming to build long-term relationships and support companies across multiple stages and milestones.
Third Rock Ventures is a venture capital firm that discovers, launches, and builds life sciences and biotechnology companies developing novel medicines and therapies.
Canaan is an early-stage venture capital firm backing founders with transformative ideas across technology and healthcare.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, with a portfolio of companies from early stage through growth.
F-Prime Capital Partners is a venture capital firm whose team of scientists, engineers, physicians, operators, and investors supports companies in scaling and accelerating growth.
S32 is a high-conviction venture firm that concentrates on a small set of core relationships, committing deeply and supporting founders over the long term.
EQT Life Sciences, formerly LSP, is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally. It is part of EQT Group.
Versant Ventures operates in-house Discovery Engines staffed by multidisciplinary scientists in dedicated laboratory facilities to help launch new biotechnology companies alongside academic founders.
Illumina Ventures is a venture investor focused on genomics and precision health, aiming to advance innovation and impact in human health.
Bluebird Ventures backs founders and entrepreneurs building start-ups that advance medical science.
Firms observed investing alongside Casdin Capital, from public investor directories. Shared companies are the overlap with Casdin Capital's recorded portfolio.
Similar investors
GV (formerly Google Ventures) is a venture investment firm that backs founders across many industries, aiming to build long-term relationships and support companies across multiple stages and milestones.
A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.
NJF Capital is the venture investment arm of NJF Holdings, the private investment group founded by Nicole Junkermann. It invests internationally in transformative technology companies.
Pontifax is an investment firm focused on life sciences and healthcare technologies, backing companies across all development stages from early research to clinical-stage growth.
JAZZ Venture Partners is a venture capital firm investing in companies at the intersection of technology, neuroscience, and human performance, spanning digital health, biosciences, and AI.